Roche Commits Billions to Strengthening U.S. Presence
Over the next five years, Roche will invest USD 50 billion to expand and upgrade existing facilities and build new facilities across its Pharmaceutical and Diagnostics Division in the U.S.
Roche announced in an April 22, 2025 press release that it is investing USD 50 billion into its U.S. presence over the next five years (1). Through this investment, the company will strengthen its existing U.S. footprint, comprising 13 manufacturing and 15 R&D sites across the Pharmaceutical and Diagnostics Divisions, creating over 12,000 new jobs.
Some of the investment will be used by Roche to expand and upgrade its U.S. manufacturing and distribution capabilities for its innovative medicines and diagnostics portfolio in Kentucky, Indiana, New Jersey, Oregon, and California. The sum will also be used for a new 900,000 square foot manufacturing center to support the company’s growing portfolio of next-generation weight loss medicines.
Additionally, Roche is set to build a new state-of-the-art gene therapy manufacturing facility in Pennsylvania, a new manufacturing facility for continuous glucose monitoring in Indiana, and a new R&D center in Massachusetts. Furthermore, the company’s pharmaceuticals and diagnostics R&D centers in Arizona, Indiana, and California will undergo significant expansion and upgrades.
“Roche is a Swiss company with a strong heritage in more than 130 countries globally. [The] announced investments underscore our long-standing commitment to research, development, and manufacturing in the U.S.,” said Thomas Schinecker, Roche Group CEO, in the press release (1). “We are proud of our 110-year legacy in the United States which has been a key driver for jobs, innovation, and the creation of intellectual property in the U.S., across both our Pharmaceutical and Diagnostics Divisions. Our investments of USD 50 billion over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the U.S. and around the world.”
After the various new facilities and expanded capabilities are completed and on-line, Roche will be exporting more medicines from the U.S. than it imports.
Earlier this year, on March 7, 2025, Roche also announced the launch of the Roche Genentech Innovation Center Boston, which will serve as the company’s Cardiovascular, Renal, and Metabolism (CVRM) hub (2). The center will be located at Harvard’s Enterprise Research Campus in Allston and will support some of work being done by Roche and Genentech in artificial intelligence (AI) and data science to accelerate drug discovery and development.
“Our new innovation center builds upon our long-standing collaboration with Harvard and enables us to leverage the exceptional talent in the Boston area. By investing in a new Cardiovascular, Renal, and Metabolism center of excellence, along with data science and AI capabilities at this strategic location, we aim to accelerate Roche’s and Genentech’s research efforts and leverage the Boston innovation ecosystem,” specified Schinecker in a press release about the center’s launch (2). “Roche has a significant presence in the U.S. and this new center is one of a number of research and manufacturing investments that Roche is making in the U.S. through Genentech and Diagnostics.”
References
Roche. Roche to Invest USD 50 Billion in Pharmaceuticals and Diagnostics in the United States Over the Next Five Years. Press Release, April 22, 2025.
Roche. Roche Announces Launch of Roche Genentech Innovation Center Boston Based at Harvard’s Enterprise Research Campus in Allston. Press Release, March 7, 2025.